文献速递血管炎

大血管炎仅是无风湿性多肌痛症状的巨细胞动脉炎患者复发的危险因素

Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

在比利时鲁汶大学医院2003至2020年连续诊断的238例巨细胞动脉炎患者中,169例(71%)存在大血管炎。无风湿性多肌痛症状者中,大血管炎与复发相关(aOR 3.05,95%CI 1.32-7.43,P=0.011),且总血管评分越高复发风险越高(aOR 1.09,95%CI 1.04-1.15,P=0.001);有风湿性多肌痛症状者中未见此关联。

要点

  • 238例巨细胞动脉炎患者中169例(71%)存在大血管炎,大血管炎患者更年轻且女性更多。
  • 无风湿性多肌痛症状者中,大血管炎与复发相关(aOR 3.05,P=0.011)且停用糖皮质激素概率更低(aHR 0.59,P=0.025)。
  • 有风湿性多肌痛症状者中,大血管炎与复发风险及停用糖皮质激素概率均无显著差异。

核心结论

  • 大血管炎是无风湿性多肌痛症状的巨细胞动脉炎患者复发的危险因素,总血管评分越高复发风险越高。

研究设计与样本

  • 回顾性纳入2003至2020年在比利时鲁汶大学医院连续诊断的巨细胞动脉炎患者,均在开始糖皮质激素治疗≤3天内行FDG PET影像且随访≥12个月,共238例。
  • PET扫描对7个血管区域进行视觉评分(0-3分)并计算总血管评分,大血管炎定义为任何大血管FDG摄取≥2。

主要发现

  • 238例患者中169例(71%)存在大血管炎,大血管炎患者较无大血管炎者年轻(69岁 vs 74岁,P<0.001)且女性比例更高(72% vs 49%,P=0.001)。
  • 无风湿性多肌痛症状者中,大血管炎与复发相关(aOR 3.05,95%CI 1.32-7.43,P=0.011),且停用糖皮质激素的概率更低(aHR 0.59,95%CI 0.37-0.94,P=0.025)。
  • 有风湿性多肌痛症状者中,大血管炎与无大血管炎者的复发风险无显著差异(aOR 1.20,95%CI 0.53-2.66,P=0.657),停用糖皮质激素的概率亦无显著差异(aHR 1.25,95%CI 0.75-2.09,P=0.394)。
  • 无风湿性多肌痛症状者中,总血管评分越高复发风险越高(aOR 1.09,95%CI 1.04-1.15,P=0.001);有风湿性多肌痛症状者中未见此关联(aOR 1.01,95%CI 0.96-1.07,P=0.693)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate differences in presentation and outcome of GCA patients with and without large vessel vasculitis (LVV) and according to the extent and severity of LVV. METHODS: Consecutive patients diagnosed with GCA between 2003 and 2020 who have had FDG PET imaging at diagnosis ≤3 days after initiation of glucocorticoids (GC) and followed for ≥12 months at the University Hospitals Leuven (Belgium) were included retrospectively. PET scans were visually scored (0-3) in seven vascular areas and a total vascular score (TVS) was calculated. LVV was defined as FDG uptake ≥2 in any large vessel. RESULTS: We included 238 GCA patients, of which 169 (71%) had LVV. LVV patients were younger (69 vs 74 years, P < 0.001) and more frequently female (72% vs 49%, P = 0.001). In patients without PMR symptoms, the presence of LVV was associated with relapse (aOR 3.05 [95% CI 1.32-7.43], P = 0.011) and with a lower probability of stopping GC (aHR 0.59 [95% CI 0.37-0.94], P = 0.025). However, in those with PMR symptoms, there was no difference in relapse risk (aOR 1.20 [95% CI 0.53-2.66], P = 0.657) and in the probability of stopping GC (aHR 1.25 [95% CI 0.75-2.09], P = 0.394) between patients with and without LVV. A higher TVS was associated with an increased risk of relapse (aOR 1.09 [95% CI 1.04-1.15], P = 0.001) in patients without PMR symptoms, but not in those with PMR symptoms (aOR 1.01 [95% CI 0.96-1.07], P = 0.693). CONCLUSION: LVV is a risk factor for relapse in GCA patients without PMR symptoms with a higher relapse risk in those with higher TVS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Moreel L, Betrains A, Boeckxstaens L, et al. Large vessel vasculitis is a risk factor for relapse only in giant cell arteritis patients without polymyalgia rheumatica. Rheumatology (Oxford). 2025. PMID: 39173669. doi:10.1093/rheumatology/keae456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。